Endometrial Cancer

Cancer incidence has continued to rise in the U.S. since the 1990s — particularly among women and younger adults, according to an American Cancer Society report.

Endometrial cancer has become the number one cancer diagnosis among U.S. women, particularly among the younger population, with nearly 68,000 cases and 14,000 deaths expected annually, according to Robert Wenham, MD.

Adjuvant durvalumab significantly improved PFS and OS compared with placebo among patients with limited-stage small cell lung cancer, according to study results presented at ESMO Congress.

Self-identifying transgender individuals assigned female at birth face three key barriers when seeking care for breast or gynecologic cancers, according to results of a qualitative study published in JAMA Network Open.

September is Gynecologic Cancer Awareness Month.

Despite the incidence of endometrial cancer diagnosis increasing annually, several promising approaches for treatment and diagnosis of endometrial cancer have been approved or are in development.

The addition of pembrolizumab to adjuvant chemotherapy improved DFS for certain women with newly diagnosed high-risk endometrial cancer, according to randomized phase 3 study results presented at ESMO Congress.

Genital talc powder and frequent douching were associated with an increased risk for ovarian cancer, according to a recent study.

Endometrial hyperplasia and endometrial cancer have a low incidence for women with recurrent abnormal uterine bleeding, with predictive factors being older age, nulliparity, polyp history and shorter intervals between samplings, data show.

The FDA expanded the approval of dostarlimab-gxly for treatment of endometrial cancer.